Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the gas-sensing capsule can be used to identify increased numbers and a change of the composition of microbiota or microorganisms in the gut to assess small intestinal dysbiosis

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Atmo Biosciences Pty Ltd
• Treatments: Rifaximin

Criteria

Inclusion Criteria:

Patients aged over 18 years presenting to the Department of Gastroenterology & Hepatology at the Princess Alexandra Hospital who require and are booked for an upper gastrointestinal endoscopy as part of the routine diagnostic work up of e.g. otherwise unexplained gastrointestinal symptoms.

Exclusion Criteria:

• Radiation Enteritis

• Pregnancy

• Gastric bezoar

• Swallowing disorders/dysphagia to food or pills

• Obese, with BMI over 35

• Suspected or known strictures of the GI tract

• Fistulas or physiological/mechanical GI obstruction

• GI surgery within the past 3 months

• Diverticultis

• Patients with implantable or portable electro-mechanical medical devices, e.g. pacemakers